InspireMD Announces the Distribution of CGuard™ Embolic Prevention System in South Africa
14 janv. 2019 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Jan. 14, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Receives Noncompliance Notice from NYSE American
11 janv. 2019 16h30 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Publication of Meta-Analysis Citing Benefits of Next Generation Mesh-Covered Carotid Stent Systems
18 déc. 2018 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Dec. 18, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
29 nov. 2018 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Regulatory and Reimbursement Approval of CGuard™ Embolic Prevention System in Australia
28 nov. 2018 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Nov. 28, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Upcoming Presentations at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)
13 nov. 2018 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...
InspireMD Announces Third Quarter 2018 Financial Results and Provides Corporate Update
06 nov. 2018 07h00 HE
|
InspireMD, Inc.
Presented Three-Year Data Highlighting Long-Term Safety and Efficacy of CGuard™ Embolic Prevention System On-Track to Submit U.S. IDE in Mid-2019 Company to Host Investor Conference Call at 8:00am...
InspireMD to Report Third Quarter 2018 Financial Results and Provide Business Update on Tuesday, November 6
30 oct. 2018 08h00 HE
|
InspireMD, Inc.
Conference Call Scheduled for 8am Eastern Time TEL AVIV, Israel, Oct. 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS)...
InspireMD Announces Presentation of Preliminary Cumulative Three-Year CGuard™ EPS Safety and Efficacy Data at the Transcatheter Cardiovascular Therapeutics 2018 Conference
27 sept. 2018 09h28 HE
|
InspireMD, Inc.
Preliminary Three-Year Data Continue to Show Unprecedented Safety, Efficacy and Durability of Stroke Prevention in Treating Carotid Artery Stenosis TEL AVIV, Israel, Sept. 27, 2018 (GLOBE NEWSWIRE)...
InspireMD Announces Regulatory Approval of CGuard™ Embolic Prevention System in Mexico
24 sept. 2018 08h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel, Sept. 24, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the...